Quick Takeaways
- TCG Crossover GP I, LLC filed SCHEDULE 13G/A for AN2 Therapeutics, Inc. Common Stock, $0.00001 par value (ANTX).
- Disclosed ownership: 0%.
- Date of event: 31 Dec 2024.
TCG Crossover GP I, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for AN2 Therapeutics, Inc. Common Stock, $0.00001 par value (ANTX)
- Filing Manager
- TCG Crossover GP I, LLC
- Reporting Manager
- TCG Crossover GP I, LLC
- Symbol
- ANTX
- Disclosed Ownership
- 0 shares
- Ownership
- 0%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:44:44 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"TCG Crossover GP I, LLC disclosed 0% ownership in AN2 Therapeutics, Inc. Common Stock, $0.00001 par value (ANTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TCG Crossover GP I, LLC | 0% | 0 | 0 | 0 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| TCG Crossover Fund I, L.P. | 0% | 0 | 0 | 0 | /s/ Craig Skaling | Craig Skaling, Authorized Signatory | |
| Chen Yu | 0% | 0 | 0 | 0 | /s/ Craig Skaling | Craig Skaling, as attorney-in-fact for Chen Yu |